Troglitazone-induced fulminant hepatic failure

Digestive Diseases and Sciences

Volumn 45, Issue 3, 2000, Pages 549-553

  Murphy, Elizabeth J ^a,b,c   Davern, Timothy J ^a,b,c,l   Obaid Shakil, A ^a,b,c   Shick, Lawton ^a,b,c,e   Masharani, Umesh ^a,b,c   Chow, Hsichao ^a,b,c   Freise, Chris ^a,b,c   Lee, William M ^a,b,c   Bass, Nathan M ^a,b,c   Ostapowicz, George ^c   Larson, Anne ^d   Caldwell, Cary ^e   Peters, Marion ^e   Rouillard, Smita ^m   Atillasoy, Evren ^m   Bodenheimer, Henry ^m   Schiano, Thomas ^m   McCashland, Tim ^f   Hay, J Eileen ^g   Wiesner, Russell ^g   Crippin, Jeffrey ^h   Faust, Tom ^h   Rakela, Jorge ^m   Blei, Andres ⁱ   Flamm, Steven ⁱ   Benner, Kent ^j   Han, Steven Huy Bui ^m   Martin, Paul ^m   Stribling, Risë ^m   Schiff, Eugene ^m   Fontana, Robert ^k   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Tivakaran/Chow Gastroenterol M G   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^g MAYO CLINIC   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l Division of Gastroenterology   (United States)

^m UCSF Division of Gastroenterology ^*

more..

Author keywords

Adverse effects; Diabetes mellitus; Liver failure; Liver transplantation; Thiazoles; Toxic hepatitis; Troglitazone

Indexed keywords

AMINOTRANSFERASE; TROGLITAZONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG MONITORING; FEMALE; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

CHROMANS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FAILURE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0034068059     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005405526283     Document Type: Article

References (11)

1. 1. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
2. 2. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
3. 3. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998 (letter)
4. 4. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38, 1998
5. 5. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 129:38-41, 1998
6. 6. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H: An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21:2140-2143, 1998
7. 7. Vella A, de Groen PC, Dinneen SF: Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 129:1080, 1998 (letter)
8. 8. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
9. 9. Farrell GC: Liver disease caused by drugs, anesthetics, and toxins. In Gastrointestinal Disease. M Feldman, BF Scharschmidt, MH Sleisenger (eds). Philadelphia, WB Saunders, 1998, pp 1221-1252
10. 10. Bass NM, Ockner RK: Drug-induced liver disease. In Hepatology. D Zakim, TD Boyer (eds). Philadelphia, WB Saunders, 1996, pp 962-1017
11. 11. Parke-Davis: Prescribing information for Rezulin. Parke-Davis, Morris Plains, New Jersey, July 1998